EU-101 is under clinical development by Eutilex and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EU-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EU-101 overview
EU-101 is under development for the treatment of solid tumors including non-small cell lung cancer and colorectal cancer. The therapeutic candidate is a monoclonal antibody developed based on the immunomodulatory platform technology. It is administered by intravenous route and acts by targeting 4-1BB also called CD137.
See Also:
Eutilex overview
Eutilex Co. Ltd., a clinical-stage biopharmaceutical company that develops immunotherapy technology, anti tumor T cell therapy and antibody therapeutics, and other technology products. The company is headquartered in Republic of Korea (South Korea).
For a complete picture of EU-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
